- Details
- In this discussion, Neal Shore speaks with Alicia Morgans to discuss their experiences and insights on topics ranging from survivorship to new developments in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Dr. Morgans highlights her work in the EAU session on mCRPC, outlining the significance of PARP inhibitors, the PROpel and MAGNITUDE trials, and the potential role of...
|
- Details
- Alicia Morgans speaks with Oliver Sartor about the SPLASH trial and advances in radioligand therapy. The SPLASH trial involves PSMA I&T Lutetium-177 (renamed PNT2002) for pre-chemo, metastatic CRPC patients, with some differences in dose and schedule compared to PSMA 617. In the lead-in study involving 27 PSMA PET-selected patients, the initial PSA 50 response rate was 40%, and the radiographic re...
|
- Details
- Alicia Morgans speaks with Neal Shore about advancements in treating metastatic castration-resistant prostate cancer (mCRPC). They discuss the implications of the newly approved PSMA-RLT lutetium-617, a radiopharmaceutical, adding it to a list of existing therapies such as taxane therapy, PARP inhibitors, and immunotherapies like sipuleucel-T. Dr. Shore emphasizes that monotherapy is no longer acc...
|
- Details
- Alicia Morgans interviews Karim Fizazi to discuss his presentation on the CYPIDES Phase I-II trial. The trial focuses on ODM-208, a CYP11 inhibitor developed with Orion, aimed at treating men with advanced prostate cancer who have exhausted conventional therapies and exhibit androgen receptor mutations. Dr. Fizazi explains that the compound targets the precursor enzymes for various steroids, there...
|
- Details
- Alicia Morgans speaks with Neal Shore, focusing on the PROpel study which evaluates the efficacy of Olaparib and Abiraterone versus Abiraterone alone in treating first-line metastatic castration-resistant prostate cancer. Dr. Shore expresses excitement over the positive findings, particularly the benefits seen across all patient populations, not just those with HRR mutations. The conversation delv...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference, Noel Clarke presents the role of PARP inhibitors for all patients with metastatic castration-resistant prostate cancer (mCRPC). Biographies: Noel Clarke, MBBS, FRCS, ChM, Professor of Urological Oncology, Salford Royal Hospital & The Christie NHS Foundation Trust, Manchester, UK Related Content: APCCC 2022: Debate: PARP Inhibitors for All...
|
- Details
- During the session of the 2022 Advanced Prostate Cancer Consensus Conference focusing on the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), Anwar Padhani presents risk-adapted treatment monitoring in mCRPC (which imaging methods, when and how often). Biographies: Anwar Padhani, MBBS, FRCP, FRCR, Consultant, Radiologist & Professor, Cancer Imaging, Paul Strickla...
|
- Details
- At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Neal Shore presents the role of radium-223 in the modern treatment armamentarium in metastatic castration-resistant prostate cancer (mCRPC) patients. Biographies: Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, Sout...
|
- Details
- Kim Chi presents an overview of how to read a genomics testing report during APCCC 2022. His presentation includes a discussion of prostate cancer-relevant genes, reading the FoundationOne CDx test, and more. Chi explains the importance of understanding the intricacies of the genomics report and its limitations given that tumor genomics is now a standard part of the workup for patients with advanc...
|